Featured Studies Results
Study Type: Treatment
Vaccines for Pancreatic Cancer After Chemotherapy and Prior to Surgery
https://www.facingourrisk.org/research-clinical-trials/study/318/vaccines-for-pancreatic-cancer-after-chemotherapy-and-prior-to-surgery
Clinicaltrials.gov identifier:
NCT05111353 (https://clinicaltrials.gov/show/NCT05111353)
Treatment
Vaccine study for people diagnosed with pancreatic cancer
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05646316 (https://clinicaltrials.gov/show/NCT05646316)
Treatment
People with stage I endometrial cancer who are having a hysterectomy
The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/299/the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer
Clinicaltrials.gov identifier:
NCT05961709 (https://clinicaltrials.gov/show/NCT05961709)
Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR
Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation
https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment
Clinicaltrials.gov identifier:
NCT05217446 (https://clinicaltrials.gov/show/NCT05217446)
Treatment
Study for metastatic colorectal cancer that has not yet been treated
Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer
Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Clinicaltrials.gov identifier:
NCT03607890 (https://clinicaltrials.gov/show/NCT03607890)
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study
Clinicaltrials.gov identifier:
NCT02997228 (https://clinicaltrials.gov/show/NCT02997228)
Treatment
This is a treatment study is for people with metastatic colorectal cancer
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw
Clinicaltrials.gov identifier:
NCT04008030 (https://clinicaltrials.gov/show/NCT04008030)
Treatment
People with metastatic colorectal cancer that is MSI-High
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.